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Dear  editor,
The  experience  level  of  the  physician  could  alter  the
disease  outcome.  Tsung-Ming  Chen  et  al  [1]  have  shown
that  the  survival  of  HCC  patients  was  dependent  on  the
level  of  experience  of  the  physicians  in  charge  of  these
patients.  Differences  in  survival  was  observed  in  patients
with  BCLC  A  and  BCLC  B  stages,  not  in  patients  with  BCLC
C.  The  study  was  published  before  the  introduction  of
sorafenib  in  clinical  practice.  In  the  real  world,  still  few
patients  with  advanced  HCC  are  properly  managed  by  ded-
icated  physicians  experienced  in  HCC  management,  with
still  unclear  clinical  impact  on  survival.  In  other  oncology
diseases  several  studies  have  investigated  the  impact  of  a
multidisciplinary  team  (MDT)  framework  and/or  multidis-
ciplinary  clinic  (i.e.  multiple  consultations  with  different
members  of  an  MDT  during  a  single  patient  visit)  on  patient
outcome,  assessment  and  management.  Results  have  gen-
erally  indicated  that  MDTs  and/or  multidisciplinary  clinics
were  associated  with  changes  in  staging/diagnosis,  initial
management  plans,  higher  rates  of  treatment,  shorter  time
to  treatment  after  diagnosis,  better  survival,  and  adher-
ence  to  clinical  guidelines.  For  this  reason,  we  evaluated
the  prognostic  effects  in  patients  cared  by  physicians  with
differing  experience  in  HCC  management.Please  cite  this  article  in  press  as:  Gardini  AC,  et  
plinary  team  on  clinical  outcome  in  patients  receiving
https://doi.org/10.1016/j.clinre.2018.11.005
We  enrolled  patients  receiving  sorafenib  for  advanced-
or  intermediate-stage  HCC  histologically  confirmed  or  diag-
nosed  according  to  the  American  Association  for  the  Study
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o  or  no  longer  amenable  to  locoregional  therapies  were
onsidered  for  the  present  study.  In  this  study,  we  defined
‘patients  managed  by  a  dedicated  physician’’  (DP  patients)
hose  patients  managed  by  an  oncologist  dedicated  to  HCC
atients.  Dedicated  physicians  closely  cooperated  with  the
DT,  which  was  composed  of  an  oncologist,  a  hepatologist,  a
urgeon,  a  radiologist,  a  dermatologist,  a  pathologist,  a  biol-
gist  and  a palliative  care  physician.  We  defined  ‘‘patients
ot  managed  by  a  dedicated  physician’’  (nDP  patients)  those
ho  were  managed  by  an  oncologist  not  dedicated  to  HCC
atients.  Non-dedicated  physicians  did  not  cooperate  with
he  MDT.  This  retrospective  study  was  conducted  on  77
dvanced  HCC  patients  consecutively  treated  at  our  insti-
ute  (Istituto  Scientifico  Romagnolo  per  lo  Studio  e  la  Cura
ei  Tumori  (IRST),  IRCCS,  Meldola,  Italy)  from  2011  to  2015.
mong  the  entire  cohort,  49  patients  (63.6%)  were  managed
y  one  dedicated  oncologist,  while  the  remaining  28  patients
36.4%)  were  managed  by  three  non-dedicated  oncologists.
atient  characteristics  were  well  balanced  between  the  two
roups.
Patients  managed  by  a  dedicated  physician  (DP)  had
 median  PFS  of  4.6  months  (95%  CI  2.8—6.0)  compared
o  2.0  months  (95%  CI  1.2—2.5)  for  those  not  managed  by
 dedicated  physician  (nDP)  (P  <  0.0001)  (HR  0.35,  95%  CI
.21—0.58,  P  <  0.0001)  (Fig.  1A).  DP  patients  had  a  median
S  of  13.3  months  (95%  CI  6.8—15.6)  compared  to  3.1
onths  (95%  CI  2.1—9.7)  for  nDP  patients  (P  =  0.002)  (HR
.44,  95%  CI  0.26—0.75,  P  =  0.003)  (Fig.  1B).  OS  was  indepen-
ent  of  second  line-treatment.After  adjusting  for  clinical
ovariates  (BCLC  stage,  performance  status,  meld  score,
asal  level  of  alphafetoprotein,  extraepatic  vs.  hepatic  dis-
ase,  starting  dose  of  sorafenib),  the  physician  dedicated
emained  independent  prognostic  factors  for  PFS  (HR  =  0.26,
5%  CI  0.13—0.52,  P  =  0.0001)  and  OS  (HR  =  0.34,  95%  CI
.16—0.73,  P  =  0.006).  nDP  patients  showed  a  higher  per-
entage  of  progression  at  the  first  CT  re-evaluation  than
DP  patients  (79.3%  vs.  46.9%,  respectively)  (P  =  0.008).  We
lso  observed  that  nDP  patients  showed  a  lower  percent-
ge  of  DCR  (22.7%)  than  DP  patients  (46.2%)  at  the  firstal.  Impact  of  physician  experience  and  multidisci-
 sorafenib.  Clin  Res  Hepatol  Gastroenterol  (2018),
T  re-evaluation  (P  =  0.030).Sorafenib  was  reduced  in  the
rst  two  months  of  treatment  in  DP  patients  compared  to
DP  patients  (51%  vs.  85.7%,  respectively)  (P  =  0.003).  DP
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atients  were  seen  more  frequently  in  the  first  two  months
han  nDP  patients  [median  3  consultations  (range  1—5)  vs.
 (range  1—4),  P  =  0.0002;  average  2.98  (standard  devia-
ion  1.05)  vs.  2.03  (standard  deviation  0.82),  P  <  0.0001].A
ermatologist  saw  28.5%  of  nDP  patients  against  100%  of
P  patients  for  dermal  toxicity  (P  =  0.001).  In  our  study,
e  found  that  DP  patients  had  a  better  outcome  than
DP  patients.  In  our  opinion,  there  are  two  reasons  for
his  result:  better  management  of  sorafenib-related  adverse
vents  (AEs)  and  the  presence  of  an  MDT  (19—20).
AEs  include  hand—foot  skin  reaction,  rash,  upper  and
ower  gastrointestinal  distress  (i.e.  diarrhea),  fatigue,  and
ypertension.  These  AEs  commonly  range  from  grade  1  to  3,
ccording  to  the  Common  Terminology  Criteria  for  Adverse
vents,  and  often  occur  early  in  treatment.  The  goal  of  AEs
anagement  is  to  prevent,  treat,  and/or  minimize  their
ffect,  thereby  enabling  patients  to  remain  on  treatment
nd  improve  their  quality  of  life.  Our  study  showed  that  PD
atients  have  a  smaller  dose  reduction  of  sorafenib  in  the
rst  two  months  of  therapy,  thanks  to  a  better  control  of  the
Es  by  the  dedicated  physician.
For  example,  HSFR  lesions  are  sharply  demarcated,  ery-
hematous,  edematous,  painful,  highly  tender  blisters  that
ake  walking  difficulty.  HSFR  is  dose-dependent  and  very
haracteristically  localized  in  areas  of  pressure  or  friction
n  the  skin,  adjacent  to  the  calluses.  An  appropriate  mana-
ement  of  skin  toxicity  by  an  expert  dermatologist,  would
ncrease  patient  compliance  to  treatment  and  improve  qual-
ty  of  life.
To  optimize  care,  the  patients  with  HCC  should  be  man-
ged  by  an  MDT  [2].  The  MDT  must  be  performed  by:  medical
ncologist,  hepatologist,  hepatobiliary  surgeon,  diagnostic
adiologist  and/or  an  interventional  radiologist,  pathologist,
iologist  and  palliative  care  physician  [2].
According  to  the  American  Association  for  the  Study  of
iver  Diseases  Practice  Guidelines  for  the  management  of
CC,  the  complexity  of  HCC  suggests  that  it  should  be
anaged  in  a  multidisciplinary  setting  [3].  Unfortunately,Please  cite  this  article  in  press  as:  Gardini  AC,  et  
plinary  team  on  clinical  outcome  in  patients  receiving
https://doi.org/10.1016/j.clinre.2018.11.005
ultidisciplinary  management  is  not  fully  implemented.  A
ecent  survey  in  the  United  States  found  that  only  44%  of
hysicians  regularly  adopt  a  multidisciplinary  approach  to
reat  HCC  [4].An  MDT  can  take  into  consideration  all  the  available  ther-
pies,  giving  the  patients  the  possibility  to  be  treated  in
he  most  aggressive  and  effective  way.  In  the  present  study,
atients  evaluated  in  an  MDT  received  significantly  more
ssociated  therapies  than  nPD  patients  with  a  remarkable
utcome  improvement.
A  close  interaction  between  the  hepatologist,  oncologist,
adiologist  and  surgeon  is  necessary  to  strictly  monitor  the
nderlying  liver  disease,  optimize  the  clinical  outcomes  and
hoose  the  most  effective  treatment.  Among  the  oncolo-
ist’s  responsibilities  is  the  management  of  AEs  induced  by
ystemic  drugs.
As  the  MDT  presides  over  the  entire  management  of  HCC
atients,  it  is  the  ideal  setting  for  observational  and  trans-
ational  research.  For  this  reason  the  figure  of  the  biologist
s  very  important  within  the  MDT.  Translational  research
rojects  aim  to  identify  novel  prognostic  predictors  and
olecular  targets,  and  to  facilitate  their  implementation
n  the  routine  clinical  management  of  patients  [5—10].
Our  results  showed  that  the  survival  of  patients  with
dvanced  HCC  was  dependent  on  both  the  experience  of
he  physician  and  the  multidisciplinary  approach.
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